Marshall Wace
DFTX

Marshall Wace’s Definium Therapeutics DFTX Stock Holding History

Marshall Wace’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1M Buy
1,298,946
+98,121
+8% +$2.42M 0.05% 310
2026
Q1 		$22.7M Sell
1,200,825
-1,774,877
-60% -$30.1M 0.02% 658
2025
Q4 		$39.8M Buy
2,975,702
+593,722
+25% +$7.35M 0.04% 406
2025
Q3 		$28.1M Sell
2,381,980
-1,039,244
-30% -$9.69M 0.03% 512
2025
Q2 		$22.2M Buy
3,421,224
+828,067
+32% +$5.45M 0.03% 549
2025
Q1 		$15.2M Buy
2,593,157
+91,766
+4% +$657K 0.02% 613
2024
Q4 		$17.4M Buy
2,501,391
+213,526
+9% +$1.47M 0.02% 589
2024
Q3 		$13M Buy
2,287,865
+127,662
+6% +$888K 0.02% 661
2024
Q2 		$15.6M Buy
2,160,203
+161,659
+8% +$1.41M 0.02% 576
2024
Q1 		$18.8M Buy
+1,998,544
New +$11.4M 0.03% 530
2023
Q4 		– Sell
-11,545
Closed -$36.1K – 2452
2023
Q3 		$36.1K Buy
+11,545
New +$47.5K ﹤0.01% 2102

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marshall Wace's DFTX Position: Q2 2026 in Review

Marshall Wace increased its Definium Therapeutics (DFTX) stake by 8.2% in Q2 2026, buying an estimated $2.42M and bringing the position to 1,298,946 shares worth $61.1M. The position accounts for 0.05% of the portfolio, ranked #310.

Marshall Wace first reported a position in DFTX in Q3 2023 and has held it in 11 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Marshall Wace held 1,298,946 shares of Definium Therapeutics worth $61.1M as of Q2 2026.
  • Marshall Wace bought 98,121 Definium Therapeutics shares in Q2 2026, an estimated $2.42M.
  • Definium Therapeutics made up 0.05% of Marshall Wace's portfolio in Q2 2026, its #310 holding.
  • Marshall Wace first reported a position in Definium Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.